CDH2

Across TCGA pan-cancer cohorts, CDH2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CDH2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CDH2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CDH2 is over-expressed in tumor, although a few such as KICH and PRAD show the opposite, repressed pattern.

KIRC, KICH, and BRCA are the cancer types where CDH2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDH2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+1.697	<.001	11	view →
KICH	Female	All	−3.654	<.001	8	view →
BRCA	All	II,III,IV	+1.164	<.001	8	view →
HNSC	All	All	+0.789	<.001	8	view →
THCA	Female	II,III,IV	+2.459	<.001	7	view →
LUAD	Male	All	+1.543	<.001	5	view →
LUSC	All	All	+1.289	<.001	4	view →
PRAD	All	All	−0.966	<.001	2	view →
KIRP	All	All	+0.890	.022	2	view →
READ	Female	All	−1.534	.027	1	view →
LIHC	Female	III,IV	+0.602	.045	1	view →
STAD	All	IV	−0.600	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CDH2–KIRC

Open the KIRC breakdown →